Literature DB >> 26173033

Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India.

Eshani Dewan1, Debasis Biswas2, Barnali Kakati3, S K Verma4, Aarti Kotwal3, Aroma Oberoi5.   

Abstract

BACKGROUND AND OBJECTIVES: We undertook the present study to ascertain the contributing risk factors and explore the epidemiological and mycological characteristics of opportunistic candidemia among patients with hematological malignancies. DESIGN AND SETTINGS: Observational cross-sectional study in a tertiary care center. PATIENTS AND METHODS: Consecutive patients with hematological malignancies reporting to the collaborating medical and pediatric units with a febrile episode were recruited and screened for candidemia by blood culture. Recovered Candida isolates were speciated and antifungal susceptibility testing was performed as per Clinical and Laboratory Standards Institute guideline (CLSI) guidelines M44-A. Further analysis was done for potential risk factors and compared between culture positive and negative patients.
RESULTS: Of 150 patients recruited, the majority (n=27) were between 51 and 60 years and the male to female ratio was 1.63:1. Fifteen patients (10%) were culture positive. The culture positivity was significantly higher in acute lymphocytic leukemia (ALL) than in non-ALL patients (p=0.03). There was significant association of candidaemia with leucopenia, chemotherapeutic drugs, corticosteroids and presence of indwelling devices. Duration of disease (p=0.032) and duration of hospitalization (p=0.003) were significantly prolonged in culture positive patients. C. tropicalis was the commonest isolate (46.67%), with non- Candida albicans outnumbering C. albicans in all categories of hematological malignancies (2.75:1). All isolates of C. albicans were uniformly sensitive to all the azoles, but only 50% were sensitive to amphotericin B and none to nystatin and flucytosine.
CONCLUSIONS: This observational study identifies ALL and chronic lymphocytic leukemia (CLL) as the forms of hematological malignancy predominantly associated with candidemia; specifies risk factors and chemotherapeutic agents predisposing patients towards its occurrence; reports a preponderance of C. tropicalis among the causative agents and finds voriconazole to be the most effective antifungal agent against the recovered isolates. This information could assist in tailoring prophylactic and therapeutic antifungal practices for this infection, according to local epidemiological and mycological characteristics.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Antifungal resistance; Candida infections; Candida tropicalis; Hematological malignancies; Non-Candida albicans

Mesh:

Substances:

Year:  2015        PMID: 26173033     DOI: 10.1016/j.hemonc.2015.06.006

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  4 in total

1.  Factors Associated to Invasive Fungal Infection in Hispanic Patients with Hematological Malignancies.

Authors:  Rafael de León-Borrás; Esteban DelPilar-Morales; Nicole Rivera-Pérez; Mara Pallens-Feliciano; Maribel Tirado-Gómez; Lorena González-Sepúlveda; Jorge Bertrán-Pasarell
Journal:  Bol Asoc Med P R       Date:  2017

2.  Candidemia in non-ICU surgical wards: Comparison with medical wards.

Authors:  Antonio Vena; Emilio Bouza; Maricela Valerio; Belén Padilla; José Ramón Paño-Pardo; Mario Fernández-Ruiz; Ana Díaz Martín; Miguel Salavert; Alessandra Mularoni; Mireia Puig-Asensio; Patricia Muñoz
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

3.  Application of Dynamic Enhanced Magnetic Resonance Imaging in the Diagnosis of Hematological Malignancies.

Authors:  Yanping Shao; Xueping Bao; Caifang Song; Danping Cui
Journal:  J Healthc Eng       Date:  2021-12-23       Impact factor: 2.682

4.  Case report: nosocomial fungemia caused by Candida diddensiae.

Authors:  Seong Eun Kim; Sook In Jung; Kyung-Hwa Park; Yong Jun Choi; Eun Jeong Won; Jong Hee Shin
Journal:  BMC Infect Dis       Date:  2020-05-27       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.